---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-22-015279"
form_type: "8-K"
ticker: "ZOMDF"
cik: "0001684144"
company_name: "Zomedica Corp."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T20:37:30.842631+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Zomedica Q3 revenue $4.78M, net loss $5.0M; cash $158.5M

## Summary
- Total revenue $4.78M (vs $0.02M Q3 2021); gross margin 75%.
- Net loss $5.0M ($0.005/shr) vs $6.35M loss prior year.
- Cash, equivalents, and AFS securities $158.5M at Sep 30, 2022.
- Closed acquisitions of Revo 2 imaging assets and Assisi LOOP/Calmer Canine product lines.
- PulseVet small animal unit sales up 225% YoY; TRUFORMA revenue up 350% YoY.

## SEC filing metadata
- accession: 0001654954-22-015279
- form_type: 8-K
- ticker: ZOMDF
- cik: 0001684144
- company_name: Zomedica Corp.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1684144/000165495422015279/0001654954-22-015279-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1684144/000165495422015279/zom_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-22-015279
- JSON: https://secwatch.observer/filing/0001654954-22-015279.json
- Plain text: https://secwatch.observer/filing/0001654954-22-015279.txt

## Key facts
- Earnings Releases
  Zomedica Corp. reported the three months ended September 30, 2022 results: revenue $4.78 million, net income $5.00 million, EPS $0.005 per share.
  - Period: the three months ended September 30, 2022
  - Revenue: $4.78 million
  - Net income: $5.00 million
  - EPS: $0.005 per share
  - Result: reported results
  source text: Summary Third Quarter 2022 Results Zomedica reported a net loss for the three months ended September 30, 2022, of $5.00 million, or $0.005 per share, compared to a net loss of $6.35 million, or $0.006 per share, for the three months ended September 30, 2021, a decrease in losses of $1.35 million or approximately 21%. Zomedica reported a net loss for the nine months ended September 30, 2022, of $14.21 million, or $0.014 per share, compared to a net loss of $15.09 million, or $0.050 per share, after adjustments for equity charges, for the nine months ended September 30, 2021, a decrease in losses of $0.88 million or approximately 6%. Revenue for the three months ended September 30, 2022, was $4.78 million, compared to $0.02 million for the three months ended September 30, 2021, an increase of $4.76 million or approximately 23,800%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1684144/000165495422015279/0001654954-22-015279-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.